ArticleCytoJournal2024
Identification of transcription factors associated with the disease-free survival of triple-negative breast cancer through weighted gene co-expression network analysis.
Article in CytoJournal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Immune checkpoint inhibition in breast cancer: targeting PD-1/PD-L1 pathway for therapeutic advances.Breast cancer (Tokyo, Japan) · 2026Review
- AI-driven CRISPR strategies in breast cancer: Organoid modeling, adaptive editing, and precision delivery.Iranian journal of basic medical sciences · 2026Review
- Pan-cancer analysis of ARNT2 and its oncogenic role in cervical cancer.Journal of gynecologic oncology · 2025Article
- Interactions between LncRNAs and MAPK signaling pathways in the pathogenesis of breast cancer.Cancer cell international · 2025Review
- Isodeoxyelephantopin Promotes Cell Death in Triple-Negative Breast Cancer by Blocking STAT3 Phosphorylation and Enhancing the Effectiveness of Paclitaxel.Food science & nutrition · 2025Article
- Controversial Role of Opioids: From Pain Control to Cancer Recurrence in Breast Cancer.Current cancer drug targets · 2025Review
- Stage-specific biomarkers in triple-negative breast cancer: Preliminary findings from bioinformatics approaches.Cancer biomarkers : section A of Disease markersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Triple-negative breast cancer (TNBC) is a subtype of breast cancer that has a worse prognosis than the other subtypes of breast cancer because of its high recurrence and metastasis rates. The objective of this study is to identify the regulatory factors that are associated with the disease-free survival (DFS) of TNBC and potential biomarkers for TNBC treatment. Material and Methods: We obtained the GSE97342 dataset from the Gene Expression Omnibus website and conducted weighted gene co-expression network analysis (WGCNA) to identify modules associated with the DFS of TNBC. Subsequently, biological functions of the modules were elucidated through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Cross-checking with the Human Transcription Factor Database facilitated the selection of hub transcription factors through univariate Cox regression analysis of overlapping transcription factors. Utilizing bioinformatics analysis, we assessed the prognostic significance of these hub transcription factors, investigated their target genes, and explored their associations with tumor immune cells in TNBC. Finally, the expression levels of the hub transcription factors were validated by immunohistochemical staining, quantitative reverse transcription polymerase chain reaction (qRT-PCR), and Western blotting. Results: Through WGCNA analysis, we identified three modules correlated with DFS in TNBC. GO and KEGG analyses elucidated the biological functions of genes within these modules. Survival analysis pinpointed three hub transcription factors: Forkhead box D1 (FOXD1), aryl hydrocarbon receptor nuclear translocator 2 (ARNT2), and zinc finger protein 132 (ZNF132). The expression level of FOXD1 was negatively associated with the prognoses of patients with TNBC, whereas the other two genes were positively associated with the prognoses of patients with TNBC. Immunohistochemical staining, qRT-PCR, and Western blotting validated the expression levels of the hub transcription factors. Conclusion: We discovered three hub transcription factors (FOXD1, ARNT2, and ZNF132) that were correlated with the DFS of TNBC. These correlations suggested their potential as prognostic predictors for patients with TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.